Best Immunotherapy with Keytruda (Pembolizumab) oncologists: TOP 55 doctors

• Specializes in immunotherapy with Keytruda for various cancers.
• Trained in immunooncology in the UK and Israel.
• Certified by the European Society of Medical Oncology (ESMO).
• Member of ESMO and European School of Oncology.
• Fluent in English, Turkish, and Russian (B1 level).

• Specializes in immunotherapy with Keytruda for various cancers.
• Trained in Turkey and the USA at MD Anderson Cancer Center.
• Certified in Medical Oncology, member of several oncology societies.
• Fluent in English and Turkish, enhancing communication with diverse patients.
• Uses patient-specific treatment planning for Keytruda administration.

• Specializes in immunotherapy with Keytruda for hematologic cancers.
• Trained in Japan and Turkey, enhancing his expertise in advanced therapies.
• Member of several international hematology and oncology associations.
• Published extensively on hematologic malignancies and treatment methods.
• Holds a PhD in Hematology from Japan Mie Medical Faculty.

• Dr. Ralf Buhl specializes in immunotherapy with keytruda (pembrolizumab) for cancer treatment.
• He has international practice experience in China and the United States.
• Dr. Buhl is a recognized expert in non-invasive cancer treatments.
• He is a member of several prestigious medical organizations.
• Dr. Buhl is a Doctor of Medical Sciences with numerous scientific publications.

• Dr. Manuela Seifert specializes in immunotherapy with pembrolizumab for breast cancer treatment.
• Trained in Germany, Dr. Seifert brings international expertise to her practice.
• Recognized for her excellence in breast cancer treatment and innovative approaches.
• Certified in gynecology and obstetrics, and a member of leading medical organizations.
• Dr. Seifert's empathetic care ensures personalized treatment plans for each patient.

• Dr. Pelles Sharon specializes in immunotherapy with keytruda (pembrolizumab) for cancer treatment.
• Utilizes precise biomarker testing to tailor keytruda (pembrolizumab) therapy for individual patients.
• Received advanced training in immunotherapy in the USA and Germany.
• Certified by the American Board of Oncology and a member of the European Society for Medical Oncology.
• Speaks English, German, and Hebrew fluently.

Prof. Dr. Birol Baytan is a respected pediatric hematologist. He focuses on diagnosing and treating childhood cancers, leukemia, anemia, and bleeding disorders. He graduated from Ankara University Medical Faculty in 1992. He completed his specialization at Uludağ University Faculty of Medicine, Department of Child Diseases.

Prof. Baytan has published 15 articles in international journals. He has presented and published 9 full texts at international scientific meetings. He has contributed to 3 books or book chapters. He has also published 8 articles in local journals. These achievements show his strong academic presence in pediatric hematology.

• Dr. David Sarid specializes in immunotherapy with pembrolizumab for different types of cancer.
• He trained in Israel, the UK, and Georgia, which broadened his medical perspective.
• He is a member of the European Society for Medical Oncology and the American Society of Clinical Oncology.
• He has authored over 30 articles on cancer treatment, contributing to medical research.
• He is a lecturer at Tel Aviv University, where he shares his knowledge of cancer therapies.

• Dr. Ofer Merimsky specializes in immunotherapy with keytruda (pembolizumab) for lung cancer patients.
• Trained in radiotherapy and brachytherapy at New York Hospital, USA.
• Member of the American Scientific Cancer Society and European Society of Oncology.
• Certified by the Israeli Society for Oncology and Radiotherapy.
• Active member of the American Society of Clinical Oncology (ASCO), USA.

• Specializes in immunotherapy with pembrolizumab for cancer treatment.
• Completed a fellowship in Hematology and Oncology in the USA.
• Board-certified in Internal Medicine, Hematology, and Medical Oncology.
• Published more than 30 scientific articles in medical journals.
• Director of the Bone Marrow Transplantation Department.

• Specializes in immunotherapy with keytruda (pembolizumab) for pediatric patients.
• Practiced at the City of Hope Hospital in Los Angeles and in Israel.
• Member of the American Association for Hematology and the Israeli Society for Pediatric Hematooncology.
• Published numerous papers and reports on pediatric hemato-oncology.
• Head of the Pediatric Oncohematology and Oncology Department at Dana Dwek Children’s Hospital.

• Specializes in immunotherapy with Keytruda for liver cancer treatments.
• Trained in Germany, collaborates internationally on oncology protocols.
• Certified in Surgical Oncology and General Surgery.
• Member of the International Hepato-Pancreato-Biliary Association.
• Utilizes multidisciplinary approaches with oncologists and radiologists.

Education and Career

2011 – 2015, (Internal Medicine Specialist) Istanbul University Istanbul School of Education and Career

Medicine Department of Internal Medicine

2015 – 2016, (Internal Medicine) Specialist Istanbul Haydarpasa Numune Training and Research Hospital

2016 – 2019, (Medical Oncology) Istanbul University Istanbul School of Medicine Department of Medical Oncology

2019 – 2021, (Medical Oncology Specialist) - Istanbul Haydarpasa Numune Training and Research Hospital

2021 – 2024, (Associate Professor) Marmara University School of Medicine Department of Medical Oncology

Memberships in Scientific Organizations

ASCO

ESMO

TTOD 

AVOD 

Publications

In the field of oncology, he has published over 30 peer-reviewed articles at both international and national levels.

Awards Received

EAACI The European Academy of Allergy and Clinical Immunology 2019 Best Poster Award

"The top 3rd verbal presentation, IGICC (11th International Gastrointestinal Cancers Conference – IGICC2021)"

Speeches Delivered at National Congresses, Conferences, and Symposia:

Courses, Meetings, and Certificates

ESMO certified Medical Oncologist since 2019

• Specializes in immunotherapy with Keytruda for non-Hodgkin lymphoma.
• Trained in Germany, the USA, and the UK in advanced hematological therapies.
• Certified by the American Board of Hematology.
• Member of the European Hematology Association.
• Fluent in English, German, and basic French.

Dr. Axel Stang is a professor, Head Physician of Asklepios Barmbek Clinic, with a specialization in internal medicine, oncology, and hematology. He conducts antibody and molecular therapies to reduce tumor size, and is a member of multiple organizations and societies. Dr. Stang has published articles on the effectiveness of radiofrequency ablation in treating of metastatic colon cancer, and was a member of a research group that studied the effects of liver embolization. Patients can submit a request on the Bookimed website to get a consultation with the professor.

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Dr. Auala Hubert is a board-certified medical oncologist and radiotherapist with 33 years of clinical experience. She works at Hadassah Medical Center and speaks both English and Hebrew. Dr. Hubert leads the Gastrointestinal Cancer Center. She is also a senior physician in the Oncology Department.

She earned her M.D. from Hadassah University Hospital. She holds board certifications in oncology and radiotherapy. Dr. Hubert has passed USMLE Parts I and II. She is a member of the Israel Society of Clinical Oncology, Israel Medical Society, and Israel Cancer Association. Dr. Hubert also serves on several medical and social service committees, where she helps advance cancer care.

Known Expertise 

Medical Oncologist 

Academic Position 

Senior Lecturer 

Education

Bar-Ilan University, Israel / Computational Biology 

Israeli Society for Health-Tech / Fellowship by IMA/ Innovation and Entrepreneurship in Medicine and Health-Tech 

Sheba Medical Center and Bar-Ilan University, Israel/ Genomics and Biomedical Informatics 

Semmelweis University/Doctor of Medicine 

Training and Specialization 

Clinical observership in acute oncology, early phase clinical trials and lung cancer/ Guy's and St. Thomas hospital, London, England 

Leader Shift, Executive Development Program, Tel-Aviv Sourasky Medical Center 

Fellowship Program in Innovation and Entrepreneurship in Medicine and Health-Tech 

Resident, Medical Oncology, TASMC, Israel 

6th year medical school rotations, Kaplan Medical Center, Israel 

Rotation, intensive care unit and pulmonology, Stony Brook hospital, NY, US 

Clinical Experience 

Leader of the TASMC oncology project of PSIFAS, the Israeli National Genomic Medicine Initiative 

PI for study initiator trial: T-Cell Repertoire sequencing as clinical efficacy tool for pembrolizumab (with platinum based chemotherapy) in advanced NSCLC. 

PI for study initiator trial: T-cell repertoire sequencing as a clinically efficacy tool for neoadjuvant immunotherapy plus platinum-doublet chemotherapy for resectable NSCLC. 

Representative of the National Medical Association for the National Council for the Prevention, Diagnosis and Treatment of Malignant Diseases, as well as head of the oncology field, Leumit HMO 

Consultant on drugs and operations in the field of oncology, Leumit HMO 

Member of the Helsinki Committee for Clinical Studies, TASMC 

Primary investigator (PI) in pharmaceutical phases I&III clinical trials Head of oncology day-care service, TASMC, Israel 

Molecular Tumor Board (MTB) moderator of the Israeli Lung Cancer Society 

NGS interpretation clinic alongside head of pathology, TASMC, Israel 

PI for study initiator trial: Genomic Variant of BCL-2 as a Novel Predictor of Response to Paclitaxel, TASMC, Israel 

Medical oncology clinic in the field of lung and breast cancer, TASMC, Israel

Leading sub-investigator (SI) in many phase I-III clinical trials in oncology, including intra-tumoral injections (mRNA, viruses and NO), TASMC, Israel 

Courses 

Good Clinical Practice ICH GCP R2 & Israeli MOH Guidelines Updated Course 

Point-of-Care Ultrasound course, Israeli Medical Association 

GCP training Bioforum 

GCP training Bioforum

Investigator Site Personnel ICH GCP Training Certificate - TransCelerate BioPharma 

Academic Experience 

Lecturer in the Department of Medical Education at the Faculty of Medical and Health Sciences at Tel Aviv University 

JIMS Journal Club - Instructor for students. 

Guidance of Dr. Aviv Berkovich M.D in basic science: cfDNA NGS for identification ofprimary and acquired resistance in patients with Lung Cancer and EGFR mutations. 

TASMC, Israel in collaboration with The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, NY USA 

Training team for oncology residents, TASMC, Israel 

Mentor for new intern, TASMC, Israel 

Tutor for medical students in oncology clerkships, Tel-Aviv University, Israel 

Honors 

Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel

 Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel 

Sign of honor for reserve medical personnel for the battle in Lebanon, IDF

Completion of residency final examination (shlav Beit) with honors 

Israeli society for clinical oncology and radiation therapy (ISCORT) 17 research grant competition winner 

Affiliations 

Israeli Medical Association (IMA) 

Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT) 

The Israeli Lung Cancer Group (ILCG) 

European Society of Medical Oncology (ESMO) 

International Association for the Study of Lung Cancer (IASLC) 

The International Society of Liquid Biopsy (ISLB) 

The Israeli Society for Health-Tech 

Boards 

Co-founder, board member and treasurer of the Israeli Acute Oncology Society 

Clinical Research Association Board of Directors on behalf of the Israeli Lung Cancer Group 

Member of the Trustees of Oncology Innovation, TASMC, Israel 

Doctor of Medical Service IDF 

Areas of interest 

Thoracic malignancies, 

early to late phase clinical trials, 

intra-tumoral injections, 

comprehensive genomic profiling of tumors, 

liquid biopsies: cfDNA, TCR rep-seq and epi-Genetics; 

cell therapy

Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.

She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.

Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.